Cardiff Oncology (CRDF)
(Delayed Data from NSDQ)
$4.07 USD
+0.08 (2.01%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $4.20 +0.13 (3.19%) 5:46 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CRDF 4.07 +0.08(2.01%)
Will CRDF be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CRDF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRDF
Cardiff Oncology (CRDF) Is a Great Choice for 'Trend' Investors, Here's Why
Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why
CRDF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Momentum in Cardiff Oncology (CRDF) Should Keep going
Cardiff Oncology (CRDF) Moves 20.5% Higher: Will This Strength Last?
What Makes Cardiff Oncology (CRDF) a Strong Momentum Stock: Buy Now?
Other News for CRDF
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
Cardiff Oncology Reveals Latest Cancer Research at AACR
Cardiff presents data underscoring 'significant potential' of onvansertib